Selective EP4 Antagonist Compounds for Lower-Side-Effect Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting prostaglandin E2 receptor 4 (EP4) are limited by their broad pharmacological effects, leading to unwanted side effects, and there is a need for more specific medicines to address diseases driven by PGE2 biology without generating dose-limiting toxicities.
Innovation Solution
Development of novel compounds that act as selective EP4 antagonists, which can be used in pharmaceutical compositions to treat various diseases by targeting the EP4 receptor, including abdominal aortic aneurysm, ankylosing spondylitis, Alzheimer's disease, atherosclerosis, cancer, diabetic nephropathy, endometriosis, inflammatory bowel disease, migraine, multiple sclerosis, osteoarthritis, and rheumatoid arthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad-spectrum COX inhibitors are used to target PGE2 synthesis, then anti-inflammatory effects are achieved, but dose-limiting toxicities and unwanted side effects occur
Solution Approach 1:
The patent segments the prostaglandin pathway by developing selective EP4 receptor antagonists that specifically block only the EP4 receptor subtype while leaving other prostaglandin pathways (EP1, EP2, EP3 receptors and COX-1 enzyme) intact. This segmentation allows therapeutic efficacy against PGE2-driven diseases while avoiding the broad-spectrum toxicities of non-selective COX inhibitors
Solution Approach 2:
The patent applies local quality by designing compounds with selective affinity for the EP4 receptor subtype. The chemical structures (Formulas 1 and 2 with specific substituents R1-R6) are optimized to interact specifically with EP4 receptor binding sites, creating localized therapeutic action at the target receptor while sparing other physiological pathways from inhibition
2Object-affected harmful factors
If selective EP4 antagonists are developed, then specificity and reduced side effects are achieved, but therapeutic coverage for multiple disease states must be maintained
Solution Approach 1:
The patent achieves universality by demonstrating that selective EP4 antagonists can treat multiple disease states through a common mechanism of PGE2-EP4 pathway blockade. The same compound class (Formulas 1 and 2) is applicable to inflammatory bowel disease, rheumatoid arthritis, cancer, atherosclerosis, and other PGE2-driven conditions, providing a universal therapeutic approach across diverse diseases
Data Source
AI summary
The disclosures herein relate to novel compounds of formula (1): (1) and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.